What Glenmark Pharmaceuticals does

Glenmark Pharmaceuticals Ltd. is a research-driven, global, integrated pharmaceutical company founded in 1977 and headquartered in Mumbai, India. The company operates across three segments — branded products, innovative drugs, and generics — with a stated strategic focus on three therapeutic areas: respiratory, dermatology, and oncology. Its branded portfolio includes Ryaltris (olopatadine/mometasone nasal spray for seasonal allergic rhinitis, FDA-approved in 2022 and generating nearly $100 million across all markets in 2025) and Winlevi (clascoterone 10 mg/g cream, the first new topical acne mechanism in over 40 years, licensed from Cassiopea/Cosmo and launched across key European markets in June 2026). Its generic business delivers USFDA-approved injectables including Methylene Blue, Lacosamide, Vancomycin Hydrochloride, and Progesterone Vaginal Inserts targeting the US institutional market. Innovation is concentrated in Ichnos Glenmark Innovation (IGI), a New York-based clinical-stage biotech subsidiary developing the proprietary BEAT bispecific/multispecific antibody platform; ISB 2001 was licensed to AbbVie in July 2025 for $700 million upfront and up to $1.925 billion in total milestones, and ISB 2301 is in development with IND submission planned for end-2026.

Glenmark's business model combines one-time licensing revenue (e.g., the AbbVie deal, Winlevi European in-licensing), branded specialty product sales (Ryaltris direct in the US from April 2026, Winlevi in Europe), and high-volume generic injectable sales in the US institutional channel. The company generates revenue through direct commercial subsidiaries in India, the US (Glenmark Pharmaceuticals Inc., USA), Canada, and Europe (Glenmark Specialty S.A.), supplemented by regional distribution partners across LATAM, Asia-Pacific, Middle East & Africa, and Russia & CIS. Manufacturing is supported by 11 facilities across four continents, and 16,000+ employees serve customers in 80+ countries. Out-licensing to and in-licensing from major pharmaceutical partners (AbbVie, Cassiopea/Cosmo, Hengrui, BeiGene, Jiangsu Hansoh, Caring Brands) is a structural feature of the revenue mix.

Recent Q4 FY26 results showed revenue from operations of Rs 3,760.28 crore (16.8% YoY growth) and consolidated net profit of Rs 301.41 crore; North America revenue grew 29.4% YoY to Rs 924.8 crore. Management has guided FY27 revenue to Rs 17,000-18,000 crore, and analyst projections from Motilal Oswal anticipate PAT scaling from Rs 570 crore in FY26 to Rs 2,600 crore by FY28, driven by the AbbVie upfront, Ryaltris direct commercialization, US generic launches, and European Winlevi rollout. Glenmark settled a $29.6 million US anti-trust case with state attorneys general in May 2026 (denying all allegations) and executed a Rs 223 crore intra-group transfer of nebulizer brands to wholly owned subsidiary Glenmark Healthcare Ltd. in the same period.

Name

Glenmark Pharmaceuticals

Legal name

Glenmark Pharmaceuticals Ltd.

Website

https://glenmarkpharma.com

Company type

Public

Founded year

1977

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Glenmark Pharmaceuticals is a Mumbai-headquartered, publicly listed Indian pharmaceutical company operating across branded, innovative, and generics segments focused on respiratory, dermatology, and oncology therapeutics, serving patients in 80+ countries via 16,000+ employees and 11 manufacturing facilities.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• Branded generics
• Respiratory therapeutics
• Dermatology products
• Oncology biologics

Headquarters

HQ city

Andheri

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Branded Generics: Glenmark sells branded generic pharmaceutical products across multiple therapeutic areas including respiratory, dermatology, and oncology in markets worldwide. This includes products like Winlevi, Ryaltris, and various other branded formulations.
2. Generic Pharmaceuticals: Commercialization of generic versions of established drugs in markets including the US, Europe, and emerging markets. Recent launches include Methylene Blue Injection, Lacosamide Injection, Vancomycin Hydrochloride Injection, and Progesterone Vaginal Inserts in the US.
3. Licensing Agreements: Out-licensing of innovative drug candidates to major pharmaceutical companies. Glenmark signed a landmark licensing agreement with AbbVie for ISB 2001 with $700 million upfront payment and potential total deal value of $1.925 billion.
4. Out-licensing/Partnership Revenue: Glenmark acquired European rights to Winlevi (clascoterone) from Cassiopea/Cosmo and commercializes it in key European markets. The company also pursues co-development partnerships with global pharmaceutical companies.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical company that develops, manufactures, and commercializes branded generics, generic formulations, and innovative therapeutics across three strategic therapy areas: respiratory, dermatology, and oncology. The company operates 11 manufacturing facilities across four continents, serves over 80 countries through direct commercial presence and distributor networks, and runs a clinical-stage biotechnology subsidiary (Ichnos Glenmark Innovation) developing multispecific antibody therapies using its proprietary BEAT platform.

Product overview

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company with presence across Branded, Innovative, and Generics segments. The company operates with a strategic focus on three therapeutic areas: Dermatology, Respiratory, and Oncology. Its product portfolio includes branded products (Winlevi, Ryaltris) and generic injectables (Methylene Blue, Lacosamide, Vancomycin, Progesterone Vaginal Inserts). The innovation arm, Ichnos Glenmark Innovation, develops novel multispecific antibody therapies for oncology. The company operates 11 manufacturing facilities across four continents and serves over 80 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Glenmark: Research-led global pharmaceutical company with presence across Branded, Innovative, and Generics segments focusing on respiratory, dermatology and oncology therapeutic areas

Products and services

• Winlevi (clascoterone 10 mg/g cream) Topical acne treatment cream for acne vulgaris in adults and adolescents. First topical acne therapy in over 40 years with first-in-class mechanism of action as a topical androgen receptor inhibitor, reducing sebum and inflammation.
• Ryaltris (olopatadine/mometasone nasal spray) Nasal spray for seasonal allergic rhinitis containing olopatadine and mometasone; FDA-approved in 2022; now directly commercialized in the US market.
• Methylene Blue Injection USP Generic methylene blue injection 50 mg/10 mL single-dose vial for acquired methemoglobinemia treatment. Bioequivalent to Provepharm's ProvayBlue.
• Lacosamide Injection USP Generic lacosamide injection 200 mg/20 mL single-dose vials for epilepsy treatment. Bioequivalent to UCB's Vimpat Injection.
• Vancomycin Hydrochloride Injection USP Generic vancomycin hydrochloride injection available in 500 mg/vial and 1 g/vial strengths for antibacterial therapy. Bioequivalent to Fresenius Kabi USA's reference listed drug.
• Progesterone Vaginal Inserts, 100 mg Progesterone vaginal inserts 100 mg for fertility treatments. Bioequivalent to Ferring Pharmaceuticals' Endometrin vaginal inserts.

Quantifiable outcome

• Q4 FY26 net profit increased 6,381.9% to Rs 301.41 crore vs prior year period
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Caring Brands Inc.minorOEM/ Whitelabel/ Licensing Partner · 1 May 2026Extended 5-year licensing agreement for Photocil and Hair Enzyme Booster products. Expanded from India to include LATAM (Mexico, Brazil, Colombia, Ecuador, Peru, Dominican Republic, Trinidad and Tobago), Russia, and Australia and New Zealand markets.
• SanPellegrino Cosmetics Private LimitedminorOEM/ Whitelabel/ Licensing Partner · 1 May 2026Partner in the extended 5-year licensing agreement for Photocil and Hair Enzyme Booster products, with expanded geographic reach across multiple regions.
• US State Attorneys GeneralminorOthers · 1 May 2026Glenmark Pharmaceuticals Inc. settled a legal case related to allegations of price-fixing, market allocation, and anti-competitive conduct in the US generic pharmaceutical market for $29.6 million over five years. The company denied all allegations.
• Cassiopea S.p.A. / Cosmo N.V.coreOEM/ Whitelabel/ Licensing Partner · 1 October 2025Winlevi (clascoterone 10 mg/g cream) received European Commission marketing authorization in October 2025. Glenmark Specialty S.A. launches the product in key European markets including Nordics, Central/Eastern Europe, Spain, with Portugal through a strategic partner.
• AbbViecoreStrategic or Co-development Partner · 1 July 2025Landmark out-licensing agreement for ISB 2001, Glenmark's trispecific T-cell engager asset. Deal includes $700 million upfront payment and potential total deal value of $1.925 billion. AbbVie gains rights to develop and commercialize the asset globally.
• Jiangsu Hengrui MedicineminorStrategic or Co-development PartnerChinese partnership for commercializing lung cancer and other oncology drugs in emerging markets, representing Glenmark's strategic shift toward China-India pharmaceutical collaboration.
• BeiGeneminorStrategic or Co-development PartnerPartnership for commercializing oncology drugs in emerging markets, making cutting-edge cancer therapies accessible at significantly lower costs than Western alternatives.
• Jiangsu HansohminorStrategic or Co-development PartnerChinese partnership for bringing affordable immunotherapy cancer drugs to emerging markets, including treatments priced at approximately Rs 50,000 per session compared to Rs 200,000-500,000 for Western alternatives.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with comparable US injectables portfolio and emerging market presence. Both companies compete directly in US differentiated injectables and complex generics.
• Sun Pharmaceutical Industries: India's largest specialty pharmaceutical company with overlapping portfolios in dermatology, respiratory, and oncology. Both companies operate US specialty generics businesses with comparable product launches and innovation pipelines.
• Dr. Reddy's Laboratories: Indian multinational with directly comparable generics, specialty, and biosimilars portfolio across US, Europe, and emerging markets. Both companies have invested in differentiated injectables and complex generics for the US institutional market.
• Hikma Pharmaceuticals: Specialty generic pharmaceutical company and former Ryaltris US partner for Glenmark. Hikma competes directly in US injectables and generics and is now a rival in the same respiratory nasal spray category that Glenmark has chosen to commercialize directly.
• Lupin Pharmaceuticals: Indian pharmaceutical company with comparable US generics and specialty presence. Both companies serve similar therapeutic areas including respiratory and dermatology and operate global manufacturing footprints.
• Amneal Pharmaceuticals: US-focused specialty generics and injectables company. Amneal competes directly with Glenmark in the US institutional injectable market and shares exposure to pricing pressure on differentiated generic launches.
• Cipla: Indian pharmaceutical peer with strong respiratory franchise (the same therapy area as Glenmark's Ryaltris and core strategic focus). Both companies operate across branded generics, specialty, and emerging markets with comparable global footprints and R&D investments.

Broad incumbents

• Teva Pharmaceutical Industries: Global generics and specialty pharmaceutical leader. As a much larger incumbent, Teva competes with Glenmark in US generics and specialty but operates at vastly greater scale with broader therapeutic coverage and biosimilars.
• Viatris (Mylan): Global generics and specialty pharmaceutical company formed by Mylan-Upjohn merger. Viatris competes with Glenmark in US generics, biosimilars, and specialty markets, with a comparable focus on injectables and emerging markets.

Emerging players

• Cosmo Pharmaceuticals: Specialty pharmaceutical company whose Cassiopea subsidiary licensed Winlevi to Glenmark for European commercialization. Both companies overlap in dermatology and innovative topical therapies, with Cosmo serving as Glenmark's European dermatology pipeline partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@glenmark_pharmaceuticals
• LinkedInlinkedin.com/company/glenmark-pharmaceuticals
• Instagraminstagram.com/glenmark_pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries4 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glenmark Pharmaceuticals